The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
New and emerging treatment of Staphylococcus aureus infections in the hospital setting
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beta-lactam antibiotics inactivate the PBP2 transpeptidase domain, while the PBP2 transglycosylase domain remains active and, in the case of MRSA strains, cooperates with the PBP2A transpeptidase [19].”
From Molecular Mechanisms of Drug Resistance in Staphylococcus aureus (2022) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Chavez-Bueno, S., Bozdogan, B., Katz, K., Bowlware, K. L., Cushion, N., Cavuoti, D., Ahmad, N., McCracken, G. H., & Appelbaum, P. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2283-2288.2005 · Cited by 124
Research works printed but not linked: 59
- Styers, 2006, Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States, Ann Clin Microbiol Antimicrob, 5, 2, 10.1186/1476-0711-5-2 · DOI · Paper page
- Noskin, 2005, The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database, Arch Intern Med, 165, 1756, 10.1001/archinte.165.15.1756 · DOI · Paper page
- Jevons, 1961, Celbenin-resistant staphylococci, BMJ, i, 124, 10.1136/bmj.1.5219.124-a · DOI · Paper page
- Enright, 2002, The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA), Proc Natl Acad Sci USA, 99, 7687, 10.1073/pnas.122108599 · DOI · Paper page
- Kluytmans-Vandenbergh, 2006, Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives, Clin Microbiol Infect, 12, 9, 10.1111/j.1469-0691.2006.01341.x · DOI · Paper page
- Appelbaum, 2006, The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, Clin Microbiol Infect, 12, 16, 10.1111/j.1469-0691.2006.01344.x · DOI · Paper page
- Deresinski, 2007, Counterpoint: vancomycin and Staphylococcus aureus—an antibiotic enters obsolescence, Clin Infect Dis, 44, 1543, 10.1086/518452 · DOI · Paper page
- Cosgrove, 2003, The impact of antimicrobial resistance on health and economic outcomes, Clin Infect Dis, 36, 1433, 10.1086/375081 · DOI · Paper page
- Katayama, 2000, A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus, Antimicrob Agents Chemother, 44, 1549, 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
- Ito, 2003, Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC, Drug Resist Updat, 6, 41, 10.1016/S1368-7646(03)00003-7 · DOI · Paper page
- Chambers, 1985, Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin, J Clin Invest, 76, 325, 10.1172/JCI111965 · DOI
- Ito, 2001, Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 45, 1323, 10.1128/AAC.45.5.1323-1336.2001 · DOI · Paper page
- Ma, 2002, Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains, Antimicrob Agents Chemother, 46, 1147, 10.1128/AAC.46.4.1147-1152.2002 · DOI · Paper page
- Okuma, 2002, Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community, J Clin Microbiol, 40, 4289, 10.1128/JCM.40.11.4289-4294.2002 · DOI · Paper page
- Ito, 2004, Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC, Antimicrob Agents Chemother, 48, 2637, 10.1128/AAC.48.7.2637-2651.2004 · DOI · Paper page
- Baba, 2002, Genome and virulence determinants of high virulence community-acquired MRSA, Lancet, 359, 1819, 10.1016/S0140-6736(02)08713-5 · DOI · Paper page
- Couto, 1996, Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri, Microb Drug Resist, 2, 377, 10.1089/mdr.1996.2.377 · DOI · Paper page
- Shorr, 2006, Healthcare-associated bloodstream infection: a distinct entity, Insights from a large U.S. database Crit Care Med, 34, 2588
- Siegman-Igra, 2002, Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia, Clin Infect Dis, 34, 1431, 10.1086/339809 · DOI · Paper page
- Drew, 2007, Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections, Pharmacotherapy, 27, 227, 10.1592/phco.27.2.227 · DOI
- 2004, Bad bugs, no drugs
- Powers, 2004, Antimicrobial drug development—the past, the present, and the future, Clin Microbiol Infect, 10, 23, 10.1111/j.1465-0691.2004.1007.x · DOI · Paper page
- Jones, 2002, In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci, J Antimicrob Chemother, 50, 915, 10.1093/jac/dkf249 · doi:10.1093/jac/dkf249
- Chopra, 2001, Glycylcyclines: Third generation tetracycline antibiotics, Curr Opin Pharmacol, 1, 464, 10.1016/S1471-4892(01)00081-9 · DOI
- Doan, 2006, Tigecycline: a glycylcycline antimicrobial agent, Clin Ther, 28, 1079, 10.1016/j.clinthera.2006.08.011 · DOI
- 2006, Tygacil. European Public Assessment Report
- Goldstein, 2006, In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections, Antimicrob Agents Chemother, 50, 2875, 10.1128/AAC.00286-06 · DOI
- Jones, 2005, Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol, J Chemother, 17, 593, 10.1179/joc.2005.17.6.593 · DOI
- Saravolatz, 2007, Comparative activity of telavancin against isolates of community-acquired methicillin-resistant Staphylococcus aureus, J Antimicrob Chemother, 2007, 406, 10.1093/jac/dkm211 · DOI
- 2007, Cubicin IV, Prescribing information
- Petersen, 2002, In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens, Antimicrob Agents Chemother, 46, 2595, 10.1128/AAC.46.8.2595-2601.2002 · DOI · Paper page
- 2006, Cubicin, European Public Assessment Report
- Lofland, 2004, In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698, J Antimicrob Chemother, 53, 664, 10.1093/jac/dkh129 · DOI
- Fritsche, 2005, Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance, Antimicrob Agents Chemother, 49, 1468, 10.1128/AAC.49.4.1468-1476.2005 · DOI
- Lowy, 2003, Antimicrobial resistance: the example of Staphylococcus aureus, J Clin Invest, 111, 1265, 10.1172/JCI200318535 · doi:10.1172/jci200318535 · Paper page
- Hartman, 1984, Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus, J Bacteriol, 158, 513, 10.1128/JB.158.2.513-516.1984 · DOI · Paper page
- Utsui, 1985, Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 28, 397, 10.1128/AAC.28.3.397 · DOI · Paper page
- Song, 1987, Evolution of an inducible penicillin-target protein in methicillin-resistant Staphylococcus aureus by gene fusion, FEBS Lett, 221, 167, 10.1016/0014-5793(87)80373-3 · DOI · Paper page
- de Jonge, 1993, Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis, Antimicrob Agents Chemother, 37, 342, 10.1128/AAC.37.2.342 · DOI
- Pinho, 2001, An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci, Proc Natl Acad Sci USA, 98, 10886, 10.1073/pnas.191260798 · DOI · Paper page
- Berger-Bachi, 1994, Expression of resistance to methicillin, Trends Microbiol, 2, 389, 10.1016/0966-842X(94)90617-3 · DOI
- de Lencastre, 1994, Molecular aspects of methicillin resistance in Staphylococcus aureus, J Antimicrob Chemother, 33, 7, 10.1093/jac/33.1.7 · DOI
- Katayama, 2004, PBP 2a mutations producing very-high-level resistance to beta-lactams, Antimicrob Agents Chemother, 48, 453, 10.1128/AAC.48.2.453-459.2004 · doi:10.1128/aac.48.2.453-459.2004
- Moreillon, 1991, Beta-lactam antibiotics active against methicillin-resistant Staphylococcus aureus, J Infect Dis, 163, 1165, 10.1093/infdis/163.5.1165 · doi:10.1093/infdis/163.5.1165
- Franciolli, 1991, Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus, J Infect Dis, 163, 514, 10.1093/infdis/163.3.514 · DOI
- Hirano, 1991, Beta-lactam–beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci, Antimicrob Agents Chemother, 35, 685, 10.1128/AAC.35.4.685 · doi:10.1128/aac.35.4.685
- Chambers, 1995, In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a, Antimicrob Agents Chemother, 39, 462, 10.1128/AAC.39.2.462 · doi:10.1128/aac.39.2.462
- Que, 1998, The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus, J Infect Dis, 177, 146, 10.1086/513805 · doi:10.1086/513805
- Lim, 2002, Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus, Nat Struct Biol, 9, 870
- Tomasz, 2003, ‘Intelligence coup’ for drug designers: crystal structure of Staphylococcus aureus beta-lactam resistance protein PBP2A, Lancet, 361, 795, 10.1016/S0140-6736(03)12719-5 · DOI
- Guignard, 2005, Beta-lactams against methicillin-resistant Staphylococcus aureus, Curr Opin Pharmacol, 5, 479, 10.1016/j.coph.2005.06.002 · DOI
- Bush, 2007, Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy, Expert Opin Investig Drugs, 16, 419, 10.1517/13543784.16.4.419 · DOI
- Glinka, 2002, Novel cephalosporins for the treatment of MRSA infections, Curr Opin Investig Drugs, 3, 206
- Hebeisen, 2001, In vitro and in vivo properties of Ro 63–9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci, Antimicrob Agents Chemother, 45, 825, 10.1128/AAC.45.3.825-836.2001 · DOI · Paper page
- Deshpande, 2004, Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates, Diagn Microbiol Infect Dis, 50, 73, 10.1016/j.diagmicrobio.2004.04.011 · doi:10.1016/j.diagmicrobio.2004.04.011
- Zbinden, 2002, In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters, Antimicrob Agents Chemother, 46, 871, 10.1128/AAC.46.3.872-875.2002 · doi:10.1128/aac.46.3.872-875.2002
- Noel, 2008, Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, Antimicrob Agents Chemother, 52, 37, 10.1128/AAC.00551-07 · DOI · Paper page
- Noel, 2008, A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections, Clin Infect Dis, 46, 647, 10.1086/526527 · DOI · Paper page
- Lipsky, 2004, Diagnosis and treatment of diabetic foot infections, Clin Infect Dis, 39, 885, 10.1086/424846 · DOI · Paper page
Cited by
Molecular Mechanisms of Drug Resistance in Staphylococcus aureus
Mlynarczyk-Bonikowska, B., Kowalewski, C., Krolak-Ulinska, A., & Marusza, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158088 · Cited by 412
Freire-Moran, L., Aronsson, B., Manz, C., Gyssens, I. C., So, A. D., Monnet, D. L., & Cars, O. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.003 · Cited by 335
Gitau, W., Masika, M., Musyoki, M., Museve, B., & Mutwiri, T. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3337-2 · Cited by 71
Metadata
- Authors
- Moreillon, P.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 14
- Pages
- 32-41
- ISSN
- 1198-743X
- Cited by
- 39
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2433 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New and emerging treatment of Staphylococcus aureus infections in the hospital setting. https://app.cochat.ai/papers/10.1111/j.1469-0691.2008.01961.x
- The paper
- Moreillon, P. (2008). New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clinical Microbiology and Infection. https://doi.org/10.1111/j.1469-0691.2008.01961.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.